Mentice AB (publ) (OM: MNTC)
Health Care · Health Care Technology · SE
Skr12.75
-4.85% today · -2.2% 1Y
Mentice AB (publ) (OM: MNTC) operates in the Health Care Technology industry within the Health Care sector. The company is valued at $39.80M and employs 109 people.
Over the last twelve months the share price has lost 2.2%, trading between 8.50 and 18.00.
Tweenvest scores Mentice AB (publ) across four factors: quality 64/100, value 48/100, growth 53/100. Its strongest factor is quality.
MNTC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $39.80M
- Revenue (TTM)
- $31.28M
- P/E
- —
- EPS
- -0.16
- Dividend yield
- —
- Beta (5Y)
- 0.46
- 52-week high
- Skr18.00
- 52-week low
- Skr8.50
- Avg volume (3M)
- —
- Shares outstanding
- 28.13M
- Employees
- 109
- Next earnings
- —
About Mentice AB (publ)
Mentice AB (publ), founded in 1998 and headquartered in Gothenburg, Sweden, specializes in delivering advanced endovascular simulation solutions. These are utilized by educational institutions, healthcare systems, and medical device manufacturers globally, with the company's operations spanning across Europe, the Middle East, Africa, the Asia Pacific region, and the Americas. Its business is structured across distinct segments focusing on the Medical Device Industry, Healthcare Systems, and Strategic Alliances. The company offers a comprehensive suite of software modules designed for training in a wide array of interventional procedures. These include acute ischemic stroke, atrial septal defect/patent foramen ovale occlusion, aortic valve implantation, endovascular aortic repair, below-the-knee, carotid, and renal interventions, along with patient-specific simulations. The portfolio further encompasses advanced and essential coronary procedures, intermediate coronary, left atrial appendage occlusion, neurovascular coiling and thrombectomy, peripheral angiography, prostatic and uterine artery embolization, radiation safety, transarterial chemoembolization, transseptal puncture, vascular trauma, and cardiac rhythm management. Additionally, Mentice provides crucial support for interventionalists transitioning from transfemoral to transradial access techniques. Beyond software, Mentice's product line features sophisticated medical simulators for endovascular therapies, accompanied by compatible accessories and extensions. They also supply specialized silicone vasculature, as well as cardiac, vascular, and neurovascular flow systems. Innovative digital offerings include the Mentice Right Heart Cath App, a mobile tool for interactive exploration of right heart catheterization procedures, and the Mentice Live Learning Center, which facilitates remote learning through its VIST G endovascular simulation platform. All these comprehensive solutions are engineered to educate, train, and significantly enhance the skills of medical professionals.
- ISIN
- SE0012673291
- Founded
- 1998
- Listed since
- Jun 18, 2019
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Health Care Technology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Veeva Systems Inc.NYSE: VEEV | $40.09B | $246.78 | -0.68% |
| Pro Medicus LimitedASX: PME | $14.25B | AU$190.60 | -1.46% |
| M3, Inc.TSE: 2413 | $7.33B | ¥1,750.00 | +1.77% |
| Sectra AB (publ)OM: SECT B | $5.62B | Skr276.20 | +0.15% |
| Waystar Holding Corp.NasdaqGS: WAY | $4.64B | $24.21 | -4.50% |
| Doximity, Inc.NYSE: DOCS | $4.41B | $24.74 | -2.21% |
| HeartFlow, Inc.NasdaqGS: HTFL | $4.34B | $49.89 | -0.62% |
| Inventurus Knowledge Solutions LimitedNSEI: IKS | $3.30B | Rs1,840.00 | +6.43% |
Figures last refreshed Aug 18, 2026.